SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-400759"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-400759" > CAIX-targeting radi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004948naa a2200457 4500
001oai:DiVA.org:uu-400759
003SwePub
008200103s2019 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4007592 URI
0247 a https://doi.org/10.1038/s41598-019-54824-52 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Huizing, Fokko J.u Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands4 aut
2451 0a CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models
264 c 2019-12-11
264 1b Springer Science and Business Media LLC,c 2019
338 a electronic2 rdacarrier
520 a Hypoxia-induced carbonic anhydrase IX (CAIX) expression is a prognostic marker in solid tumors. In recent years many radiotracers have been developed, but a fair comparison of these compounds is not possible because of the diversity in tumor models and other experimental parameters. In this study we performed a direct in vivo comparison of three promising CAIX targeting radiotracers in xenografted head and neck cancer models. The biodistribution of [In-111]In-DOTA-ZCAIX:2 was directly compared with [In-111]In-DTPA-G250-F(ab')(2) and [In-111] In-DTPA-G250 in female BALB/C nu/nu mice bearing two HNSCC xenografts with different levels of CAIX expression. In vivo biodistribution was quantified by means of microSPECT/CT scans and ex vivo biodistribution was determined with the use of gamma-counter. Tumors were snap frozen and sections were stained for CAIX expression, vessels, hypoxia (pimonidazole) and tumor blood perfusion. Tracer uptake was significantly higher in SSCNij153 tumors compared to SCCNij185 tumors for [In-111]In-DOTA-HE3-ZCAIX:2: 0.32 +/- 0.03 versus 0.18 +/- 0.01%ID/g,(p = 0.003) 4 h p.i., for [In-111]In-DTPA-girentuximab-F(ab')(2): 3.0 +/- 0.5%ID/g and 1.2 +/- 0.1%ID/g (p = 0.03), 24 h p.i. and for [In-111]In-DTPA-girentuximab: 30 +/- 2.1%ID/g and 7.0 +/- 1.0%ID/g (p = 0.0002) 72 h p.i. SPECT imaging with both [In-111]In-DTPA-girentuximab-F(ab') 2 and [111In]In-DTPA-girentuximab showed a clear difference in tracer distribution between the two tumor models. The whole IgG, i.e. [In-111]In-DTPA-girentuximab, showed the highest tumor-to-muscle ratio. We showed that different CAIX-targeting radiotracers can discriminate a low CAIX-expressing tumor from a high CAIX-expressing head and neck cancer xenografts model. In these hypoxic head and neck xenograft models [In-111]In-DTPA-girentuximab showed the most promising results.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Garousi, Javadu Uppsala universitet,Medicinsk strålningsvetenskap4 aut0 (Swepub:uu)javga723
7001 a Lok, Jasperu Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands4 aut
7001 a Franssen, Gerbenu Radboud Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands;Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, Nijmegen, Netherlands4 aut
7001 a Hoeben, Bianca A. W.u Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands4 aut
7001 a Frejd, Fredrik Y.u Uppsala universitet,Medicinsk strålningsvetenskap,Affibody AB, Solna, Sweden4 aut0 (Swepub:uu)freni195
7001 a Boerman, Otto C.u Radboud Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands;Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, Nijmegen, Netherlands4 aut
7001 a Bussink, Johanu Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands4 aut
7001 a Tolmachev, Vladimiru Uppsala universitet,Medicinsk strålningsvetenskap4 aut0 (Swepub:uu)vladtolm
7001 a Heskamp, Sandrau Radboud Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands;Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, Nijmegen, Netherlands4 aut
7102 a Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlandsb Medicinsk strålningsvetenskap4 org
7730 t Scientific Reportsd : Springer Science and Business Media LLCg 9q 9x 2045-2322
8564 u https://doi.org/10.1038/s41598-019-54824-5y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1382508/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://www.nature.com/articles/s41598-019-54824-5.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-400759
8564 8u https://doi.org/10.1038/s41598-019-54824-5

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy